http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
-
Alnylam Pharma (ALNY) to Present Givosiran Phase 3 Data at EASL
-
Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™
-
Alnylam Pharma (ALNY) Reports Submission of CTA Application to MHRA in U.K. for ALN-AGT to Initiate Phase 1 Study
-
Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
-
Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
-
Alnylam Pharma (ALNY) ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Met Primary Efficacy Endpoint
-
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
-
Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
-
Alnylam Pharma (ALNY) Reports Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
-
Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
-
Alnylam to Webcast Presentations at Upcoming February Investor Conferences
-
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
-
Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
-
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
-
Alnylam Pharma (ALNY) Announces Settlement of Litigation with Silence Therapeutics
-
Alnylam Announces Settlement of Litigation with Silence Therapeutics
-
Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
-
Alnylam to Webcast R&D Day
-
Vir Biotechnology, Alnylam Pharmaceuticals (ALNY) Initiate Phase 1/2 Study of VIR-2218
-
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
-
Alnylam to Webcast Presentations at Upcoming Investor Conferences
-
Alnylam Pharma (ALNY) Presents Updated Phase 1/2 OLE Results for Givosiran
-
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
-
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
-
Alnylam to Webcast Presentations at Upcoming Investor Conferences
-
Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
-
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
-
Alnylam Pharma (ALNY) Reports Expansion of Alnylam Act Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1); Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study
-
Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
-
Alnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community
-
Alnylam Pharma (ALNY) to Initiate Rolling Submission of NDA and Pursue Full Approval for Givosiran
-
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
-
Alnylam Pharma (ALNY) Names Dr. Margaret Hamburg to Board
-
Alnylam Appoints Dr. Margaret Hamburg to Board of Directors
-
Alnylam Pharma (ALNY) Reports Updated Positive Results from Phase 1/2 Study of Lumasiran
-
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1
-
Alnylam Pharma (ALNY) Submits CTA Application for ALN-AAT02
-
Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1
-
Alnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting
-
Alnylam Pharma (ALNY) Reports Submission of NDA in Japan for ONPATTRO (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
-
Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO™ (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
-
Alnylam Pharma (ALNY) Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with AHP
-
Alnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria
-
Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference
-
Alnylam Pharma (ALNY) Reports Publication of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
-
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
-
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
-
Alnylam Pharma (ALNY) Reports Complete Enrollment in ENVISION Phase 3 Study of Givosiran for the Treatment of Acute Hepatic Porphyrias
